Matteo Pozzi
Prof Matteo Pozzi is an expert in Cardiology at Hôpital Louis Pradel (France). Matteo Pozzi has authored 294 publications, the most recent in 2026, and is an investigator in 19 clinical trials, 4 of them ongoing. SLR score: 875 (community average: 125). How the SLR is computed.
LeadR Profile
Cardiology
Subspecialties: Critical Care - Surgery - Public Health
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2013 - 2026
Number : 294
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
Clinical Studies 19
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 23
Ongoing Clinical Trials
4 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Monitoring Antiplatelet Drugs in Cardiac Arrest Patients NCT05730114 — myocardial infarction, pharmaceutical preparations, heart, extracorporeal membrane oxygenation, percutaneous coronary intervention, platelet aggregation, heart arrest, blood platelets, membranes, platelet aggregation inhibitors | N/A | Recruiting | 2022 |
| PRactice of VENTilation in Patients With ARDS Due to COVID 19 vs Pneumonia NCT05650957 — lung, infant, newborn, acute lung injury, lung injury, covid-19, pneumonia, intensive care units, ventilation, respiratory distress syndrome, respiratory distress syndrome, newborn, infections | N/A | Active not recruiting | 2022 |
| CardioPulmonary Resuscitation With Argon (CPAr) Trial NCT05482945 — cells, resuscitation, safety, cardiopulmonary resuscitation, heart, out-of-hospital cardiac arrest, recycling, heart arrest, therapeutics, ventilation, coma, ventilators, mechanical | Phase 2 | Recruiting | 2022 |
| LVAD Versus GDMT in Ambulatory Advanced Heart Failure Patients NCT04768322 — enzyme inhibitors, sodium-glucose transporter 2 inhibitors, angiotensin ii, receptors, angiotensin, angiotensin-converting enzyme inhibitors, heart failure, heart, symporters, peptidyl-dipeptidase a, signs and symptoms, neprilysin, receptors, mineralocorticoid, angiotensins, enzymes, heart failure, systolic, maximum tolerated dose, therapeutics, mineralocorticoids, random allocation, mineralocorticoid receptor antagonists | N/A | Recruiting | 2021 |
LeadR Networks
Main global connection map